Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride provides potassium ions, essential for maintenance of intracellular tonicity, nerve impulse transmission, cardiac, smooth, and skeletal muscle contraction, and acid-base balance. Dextrose 10% provides caloric supplementation, and sodium chloride 0.2% provides sodium and chloride ions to maintain electrolyte balance.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Fluid and electrolyte replenishment,Total parenteral nutrition,Prevention and treatment of hypokalemia
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
Intravenous infusion, rate determined by severity of hypokalemia and patient condition; typical adult dose: 10-20 m Eq potassium chloride per hour, not to exceed 40 m Eq/hour or 200 m Eq/day; solution provides 10 m Eq potassium per liter at 0.075% concentration.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
Potassium: Not applicable as a drug; physiological half-life of potassium in the body is approximately 30 hours (whole-body turnover). Dextrose: rapid metabolism, half-life <15 minutes. Sodium chloride: not applicable (electrolyte).
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Potassium is primarily excreted unchanged by the kidneys; dextrose is metabolized via glycolysis and the citric acid cycle; sodium chloride is excreted mainly by the kidneys.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Renal: >90% of potassium and chloride ions are excreted by the kidneys. Dextrose is metabolized to CO2 and water, with minimal excretion unchanged (<5% renal). Sodium chloride is renally excreted (sodium >95% reabsorbed under normal conditions).
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Potassium: negligible (<2%, albumin). Dextrose: not bound. Sodium chloride: not bound.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Potassium: 0.5 L/kg (total body water, primarily intracellular). Dextrose: 0.2 L/kg (extracellular fluid). Sodium chloride: 0.2 L/kg (extracellular fluid).
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Intravenous: 100%.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
Contraindicated in severe renal impairment (e GFR < 20 m L/min/1.73 m²) or oliguria; for moderate impairment (e GFR 20-50 m L/min/1.73 m²), reduce infusion rate by 50% and monitor serum potassium closely; avoid use in chronic kidney disease stage 4-5 unless deficiency documented.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No specific adjustment required; monitor serum potassium in hepatic impairment due to risk of hyperkalemia from reduced aldosterone metabolism in cirrhosis; in Child-Pugh class C, use with caution and reduce rate if potassium increases.
No dosage adjustment required for hepatic impairment.
Weight-based: 0.5-1 m Eq/kg per dose infused over 1-2 hours, maximum 20 m Eq per dose; concentration of 0.075% in dextrose 10% and sodium chloride 0.2% provides 10 m Eq/L potassium, adjust volume accordingly; monitor serum potassium closely.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Initiate at lower infusion rates (e.g., 5-10 m Eq/hour) due to age-related decline in renal function and increased risk of hyperkalemia; total daily dose not to exceed 100 m Eq; monitor serum potassium and renal function frequently.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Concentrated potassium chloride solutions must be diluted before use to avoid fatal hyperkalemia.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Monitor serum potassium, glucose, and electrolytes during therapy,Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia,Rapid infusion may cause hyperkalemia and cardiac arrest,Do not administer unless solution is clear and container is intact
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hyperkalemia,Renal failure with oliguria or anuria,Addison's disease,Concomitant use with potassium-sparing diuretics,Severe metabolic alkalosis,Hypersensitivity to any component
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
Avoid additional potassium supplements or potassium-rich foods without medical approval due to risk of hyperkalemia. No food interactions with dextrose or sodium chloride at this concentration. Consult dietitian for diabetic meal planning due to dextrose content.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Potassium chloride, dextrose, and sodium chloride are physiologic substances. Dextrose at 10% is hypertonic; no specific teratogenic risk is identified at standard replacement doses. However, hyperglycemia from dextrose infusion may cause fetal hyperinsulinism and macrosomia, especially in gestational diabetes. No trimester-specific risks apart from those related to electrolyte imbalances or hyperglycemia.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Potassium, dextrose, and sodium chloride are normal blood constituents; infusion does not significantly alter breast milk concentrations. M/P ratio is not applicable as endogenous. Compatible with breastfeeding; caution with maternal hyperglycemia.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Increased glomerular filtration rate in pregnancy may accelerate potassium and glucose clearance; dose based on serum electrolyte and glucose monitoring. Dextrose 10% may cause hyperglycemia; consider using lower dextrose concentrations or insulin if needed.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
This is a hypotonic IV solution with low potassium (10 m Eq/L), dextrose (10%), and sodium chloride (0.2%). Use cautiously in patients with renal impairment or hyperkalemia. Monitor serum potassium, glucose, and sodium levels. Not for rapid potassium repletion. Dextrose content may cause hyperglycemia in diabetic patients. Plastic container may leach DEHP; avoid in neonates or pregnant women if alternative exists.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
This solution is given through a vein to replace fluids, sugar, and electrolytes.,Tell your healthcare provider if you have kidney disease, diabetes, or high potassium levels.,Report any signs of infection at the IV site like redness, swelling, or pain.,Do not adjust the IV rate yourself; it is controlled by the healthcare team.,Inform your provider if you are pregnant or breastfeeding.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is a Electrolyte that works by Potassium chloride provides potassium ions, essential for maintenance of intracellular tonicity, nerve impulse transmission, cardiac, smooth, and skeletal muscle contraction, and acid-base balance. Dextrose 10% provides caloric supplementation, and sodium chloride 0.2% provides sodium and chloride ions to maintain electrolyte balance.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by severity of hypokalemia and patient condition; typical adult dose: 10-20 m Eq potassium chloride per hour, not to exceed 40 m Eq/hour or 200 m Eq/day; solution provides 10 m Eq potassium per liter at 0.075% concentration.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER is classified as Category A/B. Potassium chloride, dextrose, and sodium chloride are physiologic substances. Dextrose at 10% is hypertonic; no specific teratogenic risk is identified at standard replacement dose. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.